We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+17.35%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$610M
AUM Growth
-$23.3M
Cap. Flow
-$74.6M
Cap. Flow %
-12.24%
Top 10 Hldgs %
95.65%
Holding
23
New
3
Increased
7
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
ADAP
Adaptimmune Therapeutics
ADAP
+$4.38M
2
BIOL
Biolase, Inc.
BIOL
+$2.55M
3
ARAY icon
Accuray
ARAY
+$2.03M
4
PACB icon
Pacific Biosciences
PACB
+$1.84M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$1.48M

Top Sells

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$60.7M
2
MZOR
Mazor Robotics Ltd.
MZOR
+$10.5M
3
PGEN icon
Precigen
PGEN
+$10.2M
4
QDEL icon
QuidelOrtho
QDEL
+$3.55M
5
TSRO
TESARO, Inc.
TSRO
+$2.7M

Sector Composition

Rank Sector Weight
1 Healthcare 81.69%
2 Consumer Staples 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$133M 21.83%
1,030,825
-21,754
-2% -$2.7M
MZOR
2
DELISTED
Mazor Robotics Ltd.
MZOR
$110M 17.98%
2,219,800
-251,578
-10% -$10.5M
QDEL icon
3
QuidelOrtho
QDEL
$1.21B
$106M 17.45%
2,425,416
-102,138
-4% -$3.55M
AXDX
4
DELISTED
Accelerate Diagnostics
AXDX
$106M 17.33%
470,664
-1,289
-0.3% -$317K
PACB icon
5
Pacific Biosciences
PACB
$441M
$45.6M 7.48%
8,686,455
+427,075
+5% +$1.84M
OPK icon
6
Opko Health
OPK
$978M
$24.9M 4.09%
3,636,760
– –
AMRN
7
Amarin Corp
AMRN
$297M
$22.1M 3.62%
315,165
-6,053
-2% -$429K
VRML
8
DELISTED
Vermillion, Inc.
VRML
$17.7M 2.9%
9,825,289
+583,333
+6% +$858K
BIOL
9
DELISTED
Biolase, Inc.
BIOL
$11M 1.81%
1,466
+296
+25% +$2.55M
AGEN
10
Agenus
AGEN
$326M
$7.04M 1.16%
81,387
– –
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$7.04M 1.15%
369,403
+77,023
+26% +$1.18M
ADAP
12
DELISTED
Adaptimmune Therapeutics
ADAP
$5.75M 0.94%
+701,861
New +$4.38M
PGEN icon
13
Precigen
PGEN
$2.36B
$3.71M 0.61%
195,000
-494,002
-72% -$10.2M
CFRX
14
DELISTED
ContraFect Corporation
CFRX
$2.42M 0.4%
2,728
+1,250
+85% +$1.18M
BIIB icon
15
Biogen
BIIB
$29.8B
$1.99M 0.33%
6,368
– –
ARAY icon
16
Accuray
ARAY
$32.2M
$1.89M 0.31%
+473,256
New +$2.03M
ARNA
17
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.64M 0.27%
+64,373
New +$1.48M
AXDX
18
CALL
DELISTED
Accelerate Diagnostics
AXDX
$897K 0.15%
45,880
+8,590
+23% +$2.11M
TSRO
19
CALL
DELISTED
TESARO, Inc.
TSRO
$750K 0.12%
100,000
-376,400
-79% -$46.7M
NXTM
20
CALL
DELISTED
NxStage Medical Inc.
NXTM
$310K 0.05%
2,068,800
+1,608,000
+349% +$42.9M
AQB icon
21
AquaBounty Technologies
AQB
$4.73M
$87K 0.01%
610
– –
VANI icon
22
Vivani Medical
VANI
$115M
$61K 0.01%
2,117
– –
NXTM
23
DELISTED
NxStage Medical Inc.
NXTM
– –
-2,276,106
Closed -$60.7M

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q3 2017 Portfolio in Review

As of Q3 2017, Oracle Investment Management held 23 positions worth $610M, down 3.7% from $633M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Oracle Investment Management withdrew a net $74.6M in Q3 2017, closing 1 position and reducing 7 holdings. Its most notable exit was NxStage Medical Inc., an estimated $60.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Consumer Staples.

Against the trend, Oracle Investment Management opened a new position in Adaptimmune Therapeutics worth $5.75M.

  • Oracle Investment Management's largest Q3 2017 buy was Adaptimmune Therapeutics: 701,861 shares worth $5.75M.
  • Oracle Investment Management added most to Biolase, Inc. in Q3 2017, an estimated $2.55M increase.
  • Oracle Investment Management's biggest Q3 2017 reduction was Mazor Robotics Ltd., cutting an estimated $10.5M.
  • Oracle Investment Management fully exited NxStage Medical Inc. in Q3 2017, selling an estimated $60.7M.
  • Oracle Investment Management's ten largest holdings make up 96% of its $610M portfolio in Q3 2017.
  • Oracle Investment Management opened 3 new positions and closed 1 in Q3 2017.
  • Oracle Investment Management's portfolio value fell 3.7% quarter-over-quarter to $610M.

Based on Oracle Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.